Schrodinger Inc $ 92.36 -1.1 (-1.18%)
Warning! GuruFocus has detected 1 Severe warning sign with SDGR. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for SDGR (Schrodinger) from 2020 to Jul 11 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Schrodinger stock (SDGR) PE ratio as of Jul 11 2020 is 0. More Details
Schrodinger PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Schrodinger PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Industry Healthcare » Healthcare Providers & Services » Health Information Services NAICS : 511210 NAICS : 7372
Compare NAS:ONEM NAS:HQY NAS:CHNG NAS:INOV NAS:OMCL NAS:HMSY NAS:PINC NAS:PGNY NAS:CVET NAS:TXG NYSE:VEEV TSE:2413 NAS:CERN HKSE:01833 NYSE:TDOC SZSE:300253 XTER:COP SZSE:300451 TSE:2175 ASX:PME
Traded in other countries SDGR.USA
Address 120 West 45th Street, 17th Floor, New York, NY, USA, 10036
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. Schrodinger generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.